DESTINY-Endometrial01 Phase 3 Trial Of ENHERTU® Initiated As First-Line Therapy In Patients With HER2 Expressing Primary Advanced Or Recurrent Endometrial Cancer

RefinitivLess than 1 min read

Daiichi Sankyo Co Ltd 4568:

DESTINY-ENDOMETRIAL01 PHASE 3 TRIAL OF ENHERTU® INITIATED AS FIRST-LINE THERAPY IN PATIENTS WITH HER2 EXPRESSING PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Login or create a forever free account to read this news